ArticleScience advances2023
Cord blood-derived V
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Adipocyte-derived LTB4 programs human NKG2AJournal for immunotherapy of cancer · 2026Article
- Beyond CAR-T and oncology: broadening chimeric antigen receptor technologies across cell types and diseases.Precision clinical medicine · 2026Review
- Pre-existing activation states shape functional heterogeneity of human Vγ9Vδ2 T cells.Frontiers in immunology · 2026Article
- Mechanisms and Functions of γδ T Cells in Tumor Cell Recognition.Current oncology (Toronto, Ont.) · 2025Review
- A GD (Gamma-Delta) type of cancel culture.Immuno-oncology technology · 2024Review
- Integrative single-cell multi-omics of CD19-CARCell reports. Medicine · 2024Article
- Invariant γδTCR natural killer-like effector T cells in the naked mole-rat.Nature communications · 2024Article
- Harnessing γδ T Cells against Human Gynecologic Cancers.Life (Basel, Switzerland) · 2024Review
- γδ T-cells in human malignancies: insights from single-cell studies and analytical considerations.Frontiers in immunology · 2024Review
- Effective γδ T-cell clinical therapies: current limitations and future perspectives for cancer immunotherapy.Clinical & translational immunology · 2024Review
- Gamma/delta T cells as cellular vehicles for anti-tumor immunity.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human cord blood-derived γδ T cells (CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.